Latest Conference Articles

June 18th 2015, 6:37am

International Conference on Malignant Lymphoma

Interim PET-CT scanning was successfully used to adapt treatment regimens in patients with advanced classical Hodgkin lymphoma.

June 17th 2015, 3:07pm

International Conference on Malignant Lymphoma

Adrian Wiestner, MD, PhD, Senior Investigator, Laboratory of Lymphoid Malignancies, National Institutes of Health, National Heart, Lung, and Blood Services discusses the findings of the RESONATE II trial, which looked at chlorambucil versus ibrutinib as first-line therapy in patients older than 65 with chronic lymphocytic leukemia (CLL).

June 5th 2015, 1:23pm

ASCO Annual Meeting

The combination of lenvatinib and everolimus more than doubled progression-free survival and extended overall survival by 10.1 months compared with everolimus alone as a second-line treatment for patients with metastatic renal cell carcinoma.

June 3rd 2015, 2:35pm

ASCO Annual Meeting

Brian A. Van Tine, MD, PhD, Assistant Professor Department of Medicine Siteman Cancer Center, Washington University School of Medicine, discusses trabectedin (Yondelis) for the treatment of soft tissue sarcomas.

June 3rd 2015, 1:29pm

ASCO Annual Meeting

Progression-free survival in relapsed myeloma doubled among patients treated with carfilzomib, rather than bortezomib, in combination with dexamethasone, a randomized trial showed.

June 3rd 2015, 12:01pm

ASCO Annual Meeting

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, compares the use of anastrozole to tamoxifen in patients with ductal carcinoma in situ (DCIS).

June 3rd 2015, 11:04am

ASCO Annual Meeting

Massimo Cristofanilli, MD, Jefferson University Physician, professor, director, Breast Care Center, discusses the PALOMA3 trial.

June 3rd 2015, 9:44am

ASCO Annual Meeting

Monoclonal antibodies against PD-1 and PD-L1 have demonstrated encouraging signs of antitumor activity for patients with pretreated advanced ovarian cancer.

June 3rd 2015, 9:04am

ASCO Annual Meeting

Trabectedin reduced the risk of disease progression by 45% versus dacarbazine in patients with advanced soft tissue sarcoma.

June 2nd 2015, 4:36pm

ASCO Annual Meeting

Howard Sandler, MD, MS, FASTRO, chair, Radiation Oncology, Ronald H. Bloom Family Chair in Cancer Therapeutics, discusses results from a phase III study on docetaxel with hormonal and radiation therapy in prostate cancer.

June 2nd 2015, 9:52am

ASCO Annual Meeting

Mark A. Socinski, MD, professor of Medicine and Cardiothoracic Surgery, director, Lung Cancer Section, Division of Hematology/Oncology, clinical associate director, Lung SPORE, co-director, UPMC Lung Cancer Center of Excellence, co-leader, UPCI Lung Cancer Program, discusses a phase III study which examined nivolumab in non-small cell lung cancer (NSCLC).

June 2nd 2015, 9:23am

ASCO Annual Meeting

Jedd Wolchok, MD, PhD, chief, melanoma and immunotherapeutics service and Lloyd J. Old Chair for clinical investigation at Memorial Sloan Kettering Cancer Center, discusses the findings of the Phase III CheckMate-067 trial.

June 2nd 2015, 5:57am

ASCO Annual Meeting

Treatment with neratinib immediately following adjuvant trastuzumab plus chemotherapy modestly improved invasive disease-free survival against placebo at the cost of low-grade diarrhea in almost all patients with HER2-positive early-stage breast cancer.

June 2nd 2015, 5:35am

ASCO Annual Meeting

Alexander Spira, MD, PhD, FACP, medical oncology, hematology, Virginia Cancer Specialists, discusses the POPLAR study for non-small cell lung cancer (NSCLC).

June 1st 2015, 4:26pm

ASCO Annual Meeting

Martin Reck, MD, PhD, Head of Thoracic Oncology, Hospital Grosshansdorf, discusses the maximum severity score (MSS) of baseline patient-reported Lung Cancer Symptom Scale (LCSS) as a prognostic and predictive factor for overall survival (OS) in the phase III SQUIRE study.

June 1st 2015, 1:48pm

ASCO Annual Meeting

A landmark clinical trial that will channel patients into treatment arms based on molecular abnormalities rather than cancer types aims to test the efficacy of more than 20 drugs simultaneously in an ambitious National Cancer Institute plan to further propel oncology drug discovery into the precision medicine era.

June 1st 2015, 11:06am

ASCO Annual Meeting

At the 2015 ASCO Annual Meeting, the much heralded CancerLinQ big data system for helping oncologists more clearly understand treatment patterns and options was offered for demonstration in advance of its rollout.

June 1st 2015, 10:39am

ASCO Annual Meeting

Physicians will now have a new option for some patients who have run out of them, but whose tumors have a genomic variation matching a drug target that is FDA-approved for a different cancer.

June 1st 2015, 5:25am

ASCO Annual Meeting

Ben Creelan, MD, medical oncologist with Moffitt Cancer Center, discusses the results from a phase I study of MEDI4736, an anti-PD-L1 antibody in combination with gefitinib, an EGFR inhibitor, in patients with non-small-cell lung cancer (NSCLC).

May 31st 2015, 4:48pm

ASCO Annual Meeting

In the phase III PALOMA-3 trial, adding palbociclib to standard fulvestrant more than doubled progression-free survival in pretreated patients with HR-positive, HER2-negative breast cancer.